Enomoto, Takatoshi http://orcid.org/0000-0002-1771-6684
Tamiya, Akihiro
Matsumoto, Kinnosuke
Adachi, Yuichi
Azuma, Koji
Inagaki, Yuji
Kouno, Shunichi
Taniguchi, Yoshihiko
Saijo, Nobuhiko
Okishio, Kyoichi
Atagi, Shinji
Article History
Received: 28 April 2020
Accepted: 4 July 2020
First Online: 13 July 2020
Change Date: 22 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12094-022-02794-y
Compliance with ethical standards
:
: Akihiro Tamiya reports grants and personal fees from AstraZeneca, Ono Pharmaceutical, and Bristol-Myers Squibb and personal fees from Chugai Pharmaceutical, Eli Lilly, MSD, Taiho Pharmaceutical, Kissei, Boehringer Ingelheim, and Pfizer, all outside the submitted work. Yoshihiko Taniguchi reports grants from Ono Pharmaceutical and Bristol-Myers Squibb, all outside the submitted work. Shinji Atagi reports grants and personal fees from Chugai Pharmaceutical, MSD, Ono Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Pfizer, and BMS and personal fees from Hisamitsu and Kyowa Hakko Kirin and grants from F. Hoffmann La Roche AG, all outside the submitted work. The remaining authors have no conflict of interest.
: This study was approved by the institutional review board of the National Hospital Organization (NHO) Kinki-Chuo Chest Medical Center (approval number 2019-014).
: We used an opt-out method, so that patients and families could refuse to participate in the study.